ALNYLAM PHARMACEUTICALS, INC.

ALNY Net selling

CIK 0001178670 #636 in the set updated 18 Sep 2026

Bought (120 mo)

$23.18M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$494.46M

$20.52M on a plan · $414.53M straight out of an exercise

Sold at will

$59.42M

550 of 1094 sales

Net

−$471.29M

−$36.24M against sales at will

By person

32 insiders · 1,130 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Greenstreet Yvonne

Chief Executive Officer

—

$95.41M (163) scheduled

−$95.41M

96,102

0.0718%

$29.09M

—

MARAGANORE JOHN

Chief Executive Officer

—

$72.34M (63) scheduled

−$72.34M

230,796

0.1725%

$69.85M

+69.3%

Vaishnaw Akshay

President

—

$43.67M (67) scheduled

−$43.67M

23,289

0.0174%

$7.05M

+282.5%

Greene Barry E

President

—

$42.91M (17) scheduled

−$42.91M

70,343

0.0526%

$21.29M

+9.1%

SHARP PHILLIP A

Director

—

$36.54M (33) scheduled

−$36.54M

266,899

0.1995%

$80.78M

0.0%

Garg Pushkal

EVP Chief R&D

—

$36.41M (180) scheduled

−$36.41M

18,693

0.0140%

$5.66M

+67.0%

KEATING LAURIE

EVP, Chief Legal Officer

$751.50K (1)

$31.41M (41) scheduled

−$30.66M

5,566

0.0042%

$1.68M

+42.0%

Ausiello Dennis A

Director

—

$29.15M (21) scheduled

−$29.15M

1,582

0.0012%

$478.79K

—

Sanofi

10% owner

$21.38M (1)

—

+$21.38M

10,554,134

7.89%

$3.19B

+2.9%

Fitzgerald Kevin Joseph

CSO & EVP, Head of Research

—

$19.69M (152) scheduled

−$19.69M

20,569

0.0154%

$6.23M

+59.7%

BONNEY MICHAEL W

Director

—

$15.23M (23) scheduled

−$15.23M

16,804

0.0126%

$5.09M

—

PYOTT DAVID E I

Director

$1.03M (1)

$10.53M (9) scheduled

−$9.50M

29,482

0.0220%

$8.92M

—

Tanguler Tolga

EVP, Chief Commercial Officer

—

$8.93M (129)

−$8.93M

34,297

0.0256%

$10.38M

—

Poulton Jeffrey V.

EVP, Chief Financial Officer

—

$8.59M (123)

−$8.59M

61,824

0.0462%

$18.71M

—

PAUL STEVEN M

Director

—

$8.56M (12) scheduled

−$8.56M

1,000

0.0007%

$302.65K

0.0%

Reitan Colleen F

Director

$10.36K (2)

$8.43M (17) scheduled

−$8.41M

1,446

0.0011%

$437.63K

—

Fanucci Marsha

Director

—

$7.50M (1) scheduled

−$7.50M

136

0.0001%

$41.16K

—

Mason Michael

VP, Finance and Treasurer

—

$5.49M (7) scheduled

−$5.49M

839

0.0006%

$253.92K

+271.2%

SCHULMAN AMY W

Director

—

$5.26M (4) scheduled

−$5.26M

24,049

0.0180%

$7.28M

—

SCHIMMEL PAUL

Director

—

$4.17M (1) scheduled

−$4.17M

0

0.0000%

$0.00

—

CLARKE JOHN K

Director

—

$1.50M (4) scheduled

−$1.50M

8,891

0.0066%

$2.69M

0.0%

Franchini Indrani Lall

EVP, CLO & Secretary

—

$1.44M (13)

−$1.44M

4,133

0.0031%

$1.25M

—

McLaughlin Melissa

Chief Human Resources Officer

—

$1.27M (14) scheduled

−$1.27M

9,443

0.0071%

$2.86M

−29.3%

SUPRAN BRYAN

EVP, CLO and Secretary

—

—

—

14,565

0.0109%

$4.41M

—

Hesslein Robert W.

EVP, CLO and Secretary

—

—

—

8,002

0.0060%

$2.42M

—

HAMBURG MARGARET A

Director

—

—

—

1,582

0.0012%

$478.79K

—

BRANDICOURT OLIVIER

Director

—

—

—

1,446

0.0011%

$437.63K

—

Sigal Charles Elliott

Director

—

—

—

1,446

0.0011%

$437.63K

—

KELLOGG PETER N

Director

—

—

—

1,446

0.0011%

$437.63K

—

Bertozzi Carolyn R

Director

—

—

—

775

0.0006%

$234.55K

—

Arbuckle Stuart A

Director

—

—

—

671

0.0005%

$203.08K

—

Soni Manmeet Singh

Chief Financial Officer

—

—

—

83

<0.0001%

$25.12K

—

Individual transactions

0

Nothing of that kind in this period.

What was left out

Form 4 filings counted 461

Amendments (4/A) skipped 1

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 213

Sales straight out of an exercise 331

Sales at will 550

Transactions with no price 0

Shares from compensation/vesting 4,297,422

Sales filed before the plan box existed 57

History held since 21 Sep 2016